ACQUIRED · 2020
Who Acquired Human Longevity's Oncology Division?
NeoGenomics, Inc. · $37.0M
The acquisition
Human Longevity's Oncology Division was acquired by NeoGenomics, Inc. in 2020 for $37.0M. at 3.70× revenue.
Human Longevity's Oncology Division at time of acquisition
Revenue
$10.0M
Deal value
$37.0M
Other acquisitions by NeoGenomics, Inc.
Recent transactions by the same buyer — useful for understanding their playbook and what they typically pay.
- Genoptix Inc. · 2018 · $138.7M
Similar medical practice specialty acquisitions
- Consulting Cardiologists · acquired by Hartford HealthCare in 2026 · $3.0M
- EyeSouth Partners' Retina Business · acquired by Cencora, Inc. in 2026 · $1.10B
- OneOncology · acquired by Cencora, Inc. in 2025 · $7.40B
- OrthoAlliance · acquired by Optum / SCA Health in 2025 · $1.40B
- OrthoNY · acquired by Zenyth Partners / Evolve Orthopedic Partners in 2025 · $110.0M
Run a valuation for a similar medical practice specialty business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the medical practice specialty calculator →More on medical practice specialty valuations
- Medical Practice Specialty valuation calculator· head-term variant
- Medical Practice Specialty median multiples· real-deal benchmarks
- How to value a medical practice specialty· long-form guide
Sourced from Press releases. Full deal page.
Citation: ExitValue.ai. (2020). Human Longevity's Oncology Division acquired by NeoGenomics, Inc.. https://exitvalue.ai/acquired/human-longevitys-oncology-division